Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH2 | P05091 | 19/20 | 0.78 |
| ▸ | MAOA | P21397 | 8/20 | 0.78 |
| ▸ | MAOB | P27338 | 8/20 | 0.78 |
| ▸ | XDH | P47989 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28647879 | 0.89 | MAPT (0.65) | ALDH2MAOAMAOBXDH | |
| SCHEMBL1701078 | 0.87 | ALDH2 (1.00) | ALDH2MAOAMAOBXDH | |
| SCHEMBL4684681 | 0.85 | ALDH2 (1.00) | ALDH2MAOAMAOB | |
| SCHEMBL1701071 | 0.85 | ALDH2 (0.93) | ALDH2MAOAMAOB | |
| SCHEMBL1701105 | 0.85 | ALDH2 (0.85) | ALDH2MAOAMAOBXDH | |
| SCHEMBL1701110 | 0.84 | ALDH2 (1.00) | ALDH2MAOAMAOBXDH | |
| SCHEMBL18949838 | 0.84 | NPC1 (0.73) | ALDH2MAOAMAOBXDH | |
| Isoformonentin SCHEMBL73338 | 0.83 | XDH (1.00) | ALDH2MAOAMAOBXDH | |
| Isoformonentin SCHEMBL30105310 | 0.83 | XDH (1.00) | ALDH2MAOAMAOBXDH | |
| SCHEMBL5498133 | 0.82 | ALDH2 (0.89) | ALDH2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2981530-B1 | ENHANCED OSTEOGENIC ACTIVITY OF DAIDZEIN ANALOGS ON HUMAN MESENCHYMAL STEM CELLS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2020-02-12 | — | — | EP | claimed |
| US-9669004-B2 | Daidzein analogs as treatment for cancer | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2017-06-06 | — | — | US | claimed |
| US-20160068542-A1 | Enhanced Osteogenic Activity of Daidzein Analogs on Human Mesenchymal Stem Cells | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE | 2016-03-10 | — | — | US | claimed |
| EP-2981530-A2 | ENHANCED OSTEOGENIC ACTIVITY OF DAIDZEIN ANALOGS ON HUMAN MESENCHYMAL STEM CELLS | The Administrators of the Tulane Educational Fund (US) | 2016-02-10 | — | — | EP | claimed |
| US-20150148409-A1 | NOVEL DAIDZEIN ANALOGS AS TREATMENT FOR CANCER | XAVIER UNIVERSITY OF LOUISIANA | 2015-05-28 | — | — | US | claimed |
| US-8962679-B2 | Daidzein analogs as treatment for cancer | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2015-02-24 | — | — | US | claimed |
| WO-2014165723-A2 | ENHANCED OSTEOGENIC ACTIVITY OF DAIDZEIN ANALOGS ON HUMAN MESENCHYMAL STEM CELLS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2014-10-09 | — | — | WO | claimed |
| US-20130184475-A1 | NOVEL DAIDZEIN ANALOGS AS TREATMENT FOR CANCER | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2013-07-18 | — | — | US | claimed |
| WO-2012006563-A2 | NOVEL DAIDZEIN ANALOGS AS TREATMENT FOR CANCER | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2012-01-12 | — | — | WO | claimed |
| EP-2981530-B1 | ENHANCED OSTEOGENIC ACTIVITY OF DAIDZEIN ANALOGS ON HUMAN MESENCHYMAL STEM CELLS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2020-02-12 | — | — | EP | disclosed |
| US-9669004-B2 | Daidzein analogs as treatment for cancer | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2017-06-06 | — | — | US | disclosed |
| US-9669004-B2 | Daidzein analogs as treatment for cancer | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160068542-A1 | Enhanced Osteogenic Activity of Daidzein Analogs on Human Mesenchymal Stem Cells | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE | 2016-03-10 | — | — | US | disclosed |
| EP-2981530-A2 | ENHANCED OSTEOGENIC ACTIVITY OF DAIDZEIN ANALOGS ON HUMAN MESENCHYMAL STEM CELLS | The Administrators of the Tulane Educational Fund (US) | 2016-02-10 | — | — | EP | disclosed |
| US-8962679-B2 | Daidzein analogs as treatment for cancer | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962679-B2 | Daidzein analogs as treatment for cancer | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2015-02-24 | — | — | US | disclosed |
| WO-2014165723-A2 | ENHANCED OSTEOGENIC ACTIVITY OF DAIDZEIN ANALOGS ON HUMAN MESENCHYMAL STEM CELLS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20130184475-A1 | NOVEL DAIDZEIN ANALOGS AS TREATMENT FOR CANCER | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184475-A1 | NOVEL DAIDZEIN ANALOGS AS TREATMENT FOR CANCER | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2012006563-A2 | NOVEL DAIDZEIN ANALOGS AS TREATMENT FOR CANCER | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068542-A1 | Enhanced Osteogenic Activity of Daidzein Analogs on Human Mesenchymal Stem Cells | HPGDS, CXCL12, ALPG | ALDH2 1023/4885MAOA 2979/4885MAOB 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.